ReviewWorld journal of gastroenterology2015
Treatment strategies for colorectal carcinoma with synchronous liver metastases: Which way to go?
Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04683783 (RENACI Project), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
RENACI Project: National Registry of Liver First Approach
Who cites it
24 citing papers in PubMed, 55 citations in OpenAlex.
- Cetuximab scFv-modified 5-FU Loaded Chitosan Nanoparticles: A Novel Therapeutic Platform.Current pharmaceutical biotechnology · 2026Article
- Prognostic Factors in Colorectal Liver Metastases: An Exhaustive Review of the Literature and Future Prospectives.Cancers · 2025Review
- Integrating proteomics and machine learning reveals characteristics and risks of lymph node-independent distant metastasis in colorectal cancer.Frontiers in immunology · 2025Article
- Multisocietal European consensus on the terminology, diagnosis, and management of patients with synchronous colorectal cancer and liver metastases: an E-AHPBA consensus in partnership with ESSO, ESCP, ESGAR, and CIRSE.The British journal of surgery · 2023Article
- Exploration of novel clusters and prognostic value of immune‑related signatures and identify HAMP as hub gene in colorectal cancer.Oncology letters · 2023Article
- Cytochrome P2E1 (CYP2E1) Gene Polymorphism as a Potential Prognostic Biomarker in Colorectal Cancer.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Concurrent major hepatic resection with primary colorectal cancer increases risk of organ space infections.Surgical endoscopy · 2023Article
- Multimodal Management of Colorectal Liver Metastases: State of the Art.Oncology reviews · 2023Review
- Management of Colorectal Cancer with Synchronous Liver Metastases: An Inception Cohort Study (CoSMIC).Annals of surgical oncology · 2022Article
- Impact of Sites of Metastatic Dissemination on Survival in Advanced Gastroesophageal Adenocarcinoma.Oncology · 2022Article
- Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer, as an effective and safe alternative to surgery: a review.Translational cancer research · 2020Review
- Challenges and shifting treatment strategies in the surgical treatment of locally advanced rectal cancer.Annals of gastroenterological surgery · 2020Review
- Evaluation of MR elastography as a response parameter for transarterial chemoembolization of colorectal liver metastases.European radiology · 2020Article
- Effect of high ligation on survival of patients undergoing surgery for primary colorectal cancer and synchronous liver metastases.BJS open · 2020Article
- Plant-Derived Lectins as Potential Cancer Therapeutics and Diagnostic Tools.BioMed research international · 2020Review
- Article
- LncRNA, a novel target biomolecule, is involved in the progression of colorectal cancer.American journal of cancer research · 2019Article
- Current status of surgical treatment of colorectal liver metastases.World journal of clinical cases · 2018Review
- Stereotactic body radiotherapy using the CyberKnifeOncoTargets and therapy · 2018Review
- Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases.Chinese journal of cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo offer an up-to-date review of all available treatment strategies for patients with synchronous colorectal liver metastases (CLM).
methodsA comprehensive literature search was performed to identify articles related to the management of patients with synchronous CLM. A search of the electronic databases PubMed, MEDLINE, and Google Scholar was conducted in September 2014. The following search terms were used: synchronous colorectal liver metastases, surgery, stage IV colorectal cancer, liver-first approach, and up-front hepatectomy. These terms were employed in various combinations to maximize the search. Only articles written in English were included. Particular attention was devoted to studies and review articles that were published within the last six years (2009-2014). Additional searches of the cited references from primary articles were performed to further improve the review. The full texts of all relevant articles were accessed by two independent reviewers.
resultsPoor long-term outcomes of patients with synchronous CLM managed by a traditional treatment strategy have led to questions about the timing and sequence of possible therapeutic interventions. Thus, alternative paradigms called reverse strategies have been proposed. Presently, there are four treatment strategies available: (1) primary first approach (or traditional approach) comprises resection of the primary colorectal tumor followed by chemotherapy; subsequent liver resection is performed 3-6 mo after colorectal resection (provided that CLM are still resectable); (2) simultaneous resection of the primary colorectal tumor and CLM during a single operation presents intriguing options for a highly select group of patients, which can be associated with significant postoperative morbidity; (3) liver-first (or chemotherapy-first) approach comprises preoperative chemotherapy (3-6 cycles) followed by liver resection, adjuvant chemotherapy, and resection of the primary colorectal tumor (it is best suited for patients with asymptomatic primary tumors and initially unresectable or marginally resectable CLM); and (4) up-front hepatectomy (or "true" liver-first approach) includes liver resection followed by adjuvant chemotherapy, colorectal resection, and adjuvant chemotherapy (strategy can be offered to patients with asymptomatic primary tumors and initially resectable CLM).
conclusionNone of the aforementioned strategies appears inferior. It is necessary to establish individual treatment plans in multidisciplinary team meetings through careful appraisal of all strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.